EMulate Therapeutics Announces Issuance Of 41st Patent Covering The Design Of A Pediatric Therapeutic Device For Cancer And Other Health Indications

Issuance of U.S. Design Patent No. D944,999 S advances EMulate Therapeutics' Intellectual Portfolio to 41 issued US and foreign patents.

BELLEVUE, WA / ACCESSWIRE / March 7, 2022 / EMulate Therapeutics, Inc., a clinical-stage therapeutic device company focused on developing and commercializing innovative and distinctive therapies to address critical unmet needs in healthcare, today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Design Patent No. D944,999 S, directed to a headband design for therapeutic emission of ultra-low radio frequency energy (ulRFE®).

U.S. Design Patent No. D944,999 S covers the design of the therapeutic energy emission headband to worn on the posterior of the head and to be used in conjunction with a portable ulRFE® field therapy control device for the treatment of pediatric brain cancers.

"We are extremely pleased with the continued expansion of our patent portfolio. This new issuance represents another significant step forward in EMulate's ongoing efforts to combat rare childhood disease such as diffuse midline glioma (DMG)/diffuse intrinsic pontine glioma (DIPG) and other childhood disorders," said Chris Rivera, President and Chief Executive Officer of EMulate Therapeutics, Inc. "Our patent strategy is a critical component of our long-term plan to continue to build value in EMulate and our ulRFE platform."

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE^®) to provide safe and effective therapeutic benefits specifically targeted at the patients' underlying conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical data in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health and bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

Company Contact:

David Matteson
dmatteson@emultatetx.com
Cell: 425/478-2121

Investor Contact
James Carbonara
Hayden IR
Tel (646) 755-7412
james@haydenir.com

To learn more, please visit https://emulatetx.com/

SOURCE: EMulate Therapeutics Inc.